Black Diamond Therapeutics | 4:持股变动声明-高管 Velleca Mark A.
Black Diamond Therapeutics | 4:持股变动声明-高管 Yurasov Sergey
Black Diamond Therapeutics | 4:持股变动声明-高管 Buck Elizabeth
Black Diamond Therapeutics | 4:持股变动声明-高管 Jones Erika
Black Diamond Therapeutics | 4:持股变动声明-高管 Hatzis-Schoch Brent
Black Diamond Therapeutics | 4:持股变动声明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股变动声明-董事 Raman Prakash
Black Diamond Therapeutics | 4:持股变动声明-董事 Campbell Shannon
Black Diamond Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-T. Rowe Price Investment Management, Inc.(19.0%)
Black Diamond Therapeutics | SC 13G:超过5%持股股东披露文件-Vestal Point Capital, LP(8.9%),Ryan Wilder(8.9%)
Black Diamond Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | SC 13G:超过5%持股股东披露文件-BlackRock, Inc.(6.2%)
Black Diamond Therapeutics | 4:持股变动声明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股变动声明-董事 Campbell Shannon
Black Diamond Therapeutics | 4:持股变动声明-董事 Raman Prakash
Black Diamond Therapeutics | 4:持股变动声明-股东 Versant Venture Capital VI, L.P.
Black Diamond Therapeutics | SC 13D/A:超过5%持股股东披露文件(修正)-Versant Ventures VI GP, L.P.(7.7%),Versant Ventures VI GP-GP, LLC(7.7%)等
Black Diamond Therapeutics | SC 13G/A:超过5%持股股东披露文件(修正)-T. Rowe Price Investment Management, Inc.(18.9%)
Black Diamond Therapeutics | 4:持股变动声明-董事 Behbahani Ali
Black Diamond Therapeutics | 4:持股变动声明-董事 Raman Prakash